Drug-Eluting Stent

A novel healing-targeted drug-eluting stent was as safe and effective as a standard durable polymer DES among adults with acute and chronic coronary disease undergoing PCI, early data from the PIONEER III trial show.

One month of dual antiplatelet therapy followed by aspirin monotherapy after PCI with a polymer-free drug-coated stent was noninferior to 6 to 12 months of DAPT after PCI with a contemporary drug-eluting stent, researchers reported.

At 3 years, a paclitaxel-coated balloon was noninferior to drug-eluting stents for treatment of CAD in patients with small coronary vessels, according to new data from the BASKET-SMALL 2 trial.

At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them.

Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent.

In patients undergoing PCI with a drug-eluting stent, those whose procedures were guided by IVUS had less target vessel failure at 3 years than those whose procedures were guided by angiography, new data from the ULTIMATE trial showed.

Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.

BioFreedom stent (Biosensors) vs. Orsiro stent (Biotronik) in patients with atherosclerotic coronary artery lesions.

A novel ultrathin-strut biodegradable polymer sirolimus-eluting stent vs. a thin-strut permanent polymer everolimus-eluting stent.

Among patients who underwent PCI with a drug-eluting stent and were prescribed dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy reduced bleeding risk compared with continued DAPT regardless of DES type, according to results from the TWILIGHT-SYNERGY study.